Cancer screening is changing rapidly. In addition to mammograms, colonoscopies, Pap tests, PSA testing, and low-dose CT scans, a newer category of blood tests called multi-cancer early detection (MCED) tests is designed to look for signs associated with many different cancers from a single blood sample.

One of the best-known tests in this category is the Galleri® test from GRAIL. Galleri analyzes patterns of DNA methylation in cell-free DNA circulating in the bloodstream and looks for patterns associated with cancer. If a cancer-associated signal is detected, the test also attempts to identify the organ or tissue where that signal most likely originated.

For people in San Antonio interested in additional cancer screening, Galleri is already commercially available by prescription. However, it is important to understand both the potential advantages and the significant limitations of this technology before deciding whether testing is appropriate.

First, an Important Clarification: Is Galleri FDA Approved?

As of September 28, 2026, Galleri has not yet been cleared or approved by the U.S. Food and Drug Administration (FDA).

The FDA's Molecular and Clinical Genetics Advisory Panel met on September 23, 2026, to evaluate GRAIL's premarket approval application for Galleri. The FDA describes the test as a prescription-only, next-generation sequencing test designed to identify cancer-specific methylation patterns in cell-free DNA and intended for multi-cancer screening in adults age 50 and older.

Galleri is currently available as a laboratory-developed test performed through GRAIL's CLIA-certified and CAP-accredited laboratory. GRAIL's current patient safety information explicitly states that the test has not been cleared or approved by the FDA.

That distinction matters. Availability of a laboratory-developed test does not mean that the FDA has completed its premarket approval process.

How Does the Galleri Cancer Test Work?

Cancer cells can release fragments of DNA into the bloodstream. These fragments are part of what is known as cell-free DNA, or cfDNA.

Galleri does not primarily look for inherited cancer mutations. Instead, it examines methylation patterns on circulating DNA.

Methylation is a normal chemical process in which small chemical groups attach to DNA and help regulate which genes are active or inactive. Cancer can produce abnormal and recognizable methylation patterns. Galleri analyzes hundreds of thousands of methylation sites across relevant regions of the genome and uses computational methods to determine whether the pattern resembles one associated with cancer.

If a cancer signal is found, Galleri also predicts a Cancer Signal Origin (CSO) — the tissue or organ from which the abnormal DNA most likely originated. This information can help a physician decide what imaging, laboratory testing, endoscopy, biopsy, or specialist evaluation may be appropriate next.

Galleri itself does not diagnose cancer. A positive result requires additional diagnostic testing.

What Are the Potential Advantages of Galleri Testing?

One Blood Test Can Look for Signals Associated With Many Cancers

Traditional cancer screening generally focuses on one organ at a time. Mammography looks for breast cancer, colonoscopy and stool-based testing screen for colorectal cancer, and low-dose CT may be recommended for certain people at increased risk for lung cancer.

Galleri has detected cancer signals associated with more than 50 cancer types in clinical studies, including several cancers for which routine population-wide screening tests are not currently available.

This broader approach is one of the major reasons MCED technology has attracted so much attention.

It May Detect Cancers That Otherwise Lack Routine Screening

Some serious cancers — including pancreatic, ovarian, liver/bile duct, esophageal, and certain head-and-neck cancers — do not have broadly recommended screening programs for average-risk adults.

A blood-based MCED test creates the possibility of looking for signals from some of these cancers before symptoms prompt an evaluation.

That does not mean Galleri detects every case of these cancers or proves that earlier detection will improve outcomes in every situation. It means the test offers a new way of looking for cancer-associated biological signals across multiple organs simultaneously.

The Test Has High Specificity

In the independent CCGA validation study involving 4,077 participants, Galleri demonstrated 99.5% specificity, corresponding to a false-positive rate of approximately 0.5%.

High specificity is particularly important for a screening test. If a test generated large numbers of false alarms, healthy individuals could be exposed to unnecessary scans, procedures, biopsies, expense, and anxiety.

Galleri Can Help Identify Where a Cancer Signal May Be Coming From

Detecting a cancer-associated signal is only part of the challenge. Physicians also need to know where to investigate.

In the CCGA validation study, Galleri's prediction of the cancer signal's tissue of origin was correct in approximately 88.7% of true-positive cases.

A reasonably accurate tissue-of-origin prediction can help physicians focus the diagnostic workup rather than beginning with an unrestricted search throughout the body.

What Are the Limitations of Galleri Cancer Testing?

The limitations are just as important as the potential benefits.

A Negative Galleri Test Does Not Mean You Are Cancer-Free

Galleri does not detect every cancer.

In the CCGA validation study, overall sensitivity across cancer types and stages was approximately 51.5%. In other words, a substantial proportion of known cancers in that validation population did not produce a detectable signal.

This is why a result of "No Cancer Signal Detected" cannot rule out cancer.

Anyone experiencing concerning symptoms should still undergo appropriate medical evaluation regardless of a Galleri result.

Early-Stage Cancers Can Be Harder to Detect

One of the most important limitations involves very early cancer.

In the CCGA validation study, sensitivity increased substantially as cancer stage advanced:

• Stage I: 16.8%
• Stage II: 40.4%
• Stage III: 77.0%
• Stage IV: 90.1%

These figures come from a validation study and should not be interpreted as the expected detection rate for every individual undergoing routine screening. However, they illustrate an important biological challenge: small early cancers may release very little tumor-associated DNA into the circulation.

A blood test designed for early cancer detection can therefore miss some of the very early cancers patients most hope to find.

Sensitivity Varies Considerably by Cancer Type

Not all tumors shed the same amount of DNA into the bloodstream.

Some aggressive cancers generate detectable circulating DNA relatively early, while other tumors may be much more difficult to identify with a blood-based assay. Published evaluations have reported substantial differences in sensitivity among different cancer types.

For that reason, "screens for more than 50 cancers" should not be interpreted to mean that the test detects all 50-plus cancers equally well.

A Positive Result Is Not a Cancer Diagnosis

Galleri reports either a cancer signal detected or no cancer signal detected.

If a cancer signal is detected, additional evaluation is necessary. Depending on the predicted Cancer Signal Origin, that could involve:

• CT, MRI, ultrasound, or PET imaging
• Endoscopy or colonoscopy
• Laboratory testing
• Referral to a specialist
• Biopsy or other diagnostic procedures

The FDA materials evaluating Galleri specifically emphasize that a Cancer Signal Detected result requires established diagnostic testing to confirm whether cancer is actually present.

Occasionally, extensive follow-up testing may not find a cancer. This can create additional expense, medical procedures, and understandable anxiety.

False Positives and False Negatives Can Occur

No screening test is perfect.

A false positive occurs when Galleri detects a cancer-associated signal but subsequent evaluation does not confirm cancer.

A false negative occurs when cancer is present but Galleri reports no cancer signal.

GRAIL specifically warns patients that both types of results occur.

Galleri Does Not Replace Standard Cancer Screening

This may be the single most important point for patients to understand.

Galleri should be viewed as an additional screening tool, not a replacement for established cancer screening.

Depending on your age, sex, smoking history, family history, and other risk factors, your physician may still recommend mammography, cervical cancer screening, colorectal cancer screening, low-dose CT lung screening, prostate cancer screening discussions, or other established preventive care.

Both GRAIL and FDA materials explicitly state that Galleri should not replace recommended single-cancer screening tests.

Who Might Consider Galleri Testing?

GRAIL currently recommends Galleri for adults with an elevated risk of cancer, including people age 50 and older. The test is not recommended for people who are pregnant, age 21 or younger, or currently undergoing active cancer treatment.

Age is particularly relevant because cancer incidence rises considerably as people get older. However, the decision to undergo additional screening should be individualized.

A physician can help weigh factors such as:

• Age
• Family history of cancer
• Smoking history
• Previous cancers
• Occupational or environmental exposures
• Existing screening history
• Other medical conditions
• The potential benefits and consequences of additional diagnostic testing

Where Can You Get the Galleri Test in San Antonio?

Galleri is a prescription-only test, so it must be ordered by a healthcare provider.

San Antonio residents generally have two routes.

Galleri Testing Through a Local Healthcare Provider

A physician or other qualified healthcare provider who offers Galleri can discuss whether testing is appropriate, place the order, and help interpret the results.

MDVIP-AI, located at 115 Gallery Circle, Suite 200, San Antonio, TX 78258 in the Stone Oak area, is a concierge primary care practice that offers Galleri multi-cancer screening as part of a comprehensive, genetics-based prevention program.

Because participation and testing availability can change, patients should contact a practice directly before scheduling to confirm that Galleri is currently offered, determine the consultation process, and ask how follow-up is handled if a cancer signal is detected.

Request Galleri Directly Through GRAIL

Patients can also request the test through Galleri's website. An independent telemedicine provider reviews the request and, when appropriate, provides the prescription.

After the test has been ordered, patients can have their blood drawn through a participating laboratory or arrange for a trained technician to perform the blood collection. GRAIL's website provides a location-based tool for finding participating blood-draw locations.

How Much Does the Galleri Test Cost?

As of September 27, 2026, the price for Galleri testing is $599. Most commercial health insurance plans do not currently cover it.

GRAIL states that eligible HSA or FSA funds may be usable for the test, depending on the individual plan. Eligible TRICARE beneficiaries age 50 and older with elevated cancer risk may also have coverage subject to program requirements and prior authorization.

Because pricing, discounts, and insurance policies can change, patients should verify current costs before ordering.

What Happens After a Galleri Blood Draw?

The blood sample is sent to GRAIL's laboratory for analysis. Results are generally available approximately two weeks after the laboratory receives the sample.

There are two basic result categories:

No Cancer Signal Detected means the assay did not identify a methylation pattern associated with cancer. It does not guarantee that cancer is absent.

Cancer Signal Detected means the assay found a methylation pattern associated with cancer. The report typically provides a predicted Cancer Signal Origin to help the healthcare provider determine appropriate follow-up testing.

Either result should be interpreted in the context of the patient's overall medical history and existing cancer-screening plan.

Is Galleri Worth Considering?

Galleri represents a fundamentally different approach to cancer screening.

Rather than looking at one organ at a time, the test searches circulating DNA for cancer-associated methylation patterns across multiple cancer types using a single blood draw. Its high specificity and ability to predict the likely source of a detected cancer signal are significant technical achievements.

At the same time, Galleri has important limitations. It can miss cancer, particularly some early-stage cancers; performance varies substantially by cancer type; positive results require additional diagnostic testing; and it has not yet been proven that MCED screening will reduce cancer mortality across the general population.

Galleri also does not replace established cancer screening.

For adults in San Antonio — particularly those age 50 and older — the most useful conversation is therefore not, "Can one blood test tell me whether I have cancer?"

A better question is:

"Would adding multi-cancer early detection testing to my existing cancer-screening plan provide useful information for me?"

That decision is best made with a healthcare professional who understands both the emerging science behind cancer-associated methylated DNA and the appropriate follow-up if an abnormal signal is detected.

MDVIP-AI is a concierge primary care practice in San Antonio's Stone Oak area, accepting a limited panel of 300 patients. If you would like to discuss whether Galleri testing is appropriate for you — as part of a comprehensive, genetics-based prevention plan — contact us or call (210) 722-0527.

This article is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Galleri® is a registered trademark of GRAIL, Inc. Test availability, FDA regulatory status, pricing, and insurance coverage may change.